CDK6 (cyclin-dependent kinase 6), as one of the proto-oncogenes driving tumors, has become a key target of various cancer therapies [44], and its inhibition can significantly affect tumor cell metabolism and antitumor immunity [45, 46]. The gene discussed is CDK6; the disease is neoplasm.